$49 per month*
Subscribe to Pro or Enterprise plans to unlock this feature.
Become a smarter investor today.
Become a smarter investor today.
This statistic highlights Bristol-Myers Squibb’s Revenue Breakdown from 2016 onwards, split between Abraxane, Baraclude, Eliquis, Empliciti, Inrebic, Onureg, Opdivo, Orencia, Pomalyst/Imnovid, Reblozyl, Revlimid, Sprycel, Vidaza, Yervoy, Zeposia, and Other Brands.
Bristol-Myers Squibb’s Revenue Breakdown
|Category||Q1 2021||Q1 2020||YoY Growth||Revenue share in Q1 2021|
(All figures in millions, except percentages)
Bristol-Myers Squibb Company is a global biopharmaceutical company that produces, markets, and distributes more than 36 drugs to satisfy the medical needs of patients with serious diseases. Its pharmaceutical products include small molecule drugs in the form of a pill or tablet and Biologics administered to patients through injections. In Q1 2021, Bristol-Myers Squibb Company generated total revenue of $11,073 million. This revenue is bifurcated among different products offered by the company.
Abraxane is a cancer medicine that restricts the growth and spread of cancer cells in the body. This medicine is used to treat advanced cancer of the pancreas, lungs, and breast whose treatment has failed or which cannot be treated by surgery. It is a solvent-free protein-bound chemotherapy product that combines paclitaxel with albumin. In Q1 2021, Bristol-Myers Squibb generated $314.03 million from the Abraxane brand of which $225 million was received from the U.S. Revenue from this brand has increased by 5% year-over-year from $300.03 million in Q1 2020.
Baraclude (entecavir) is an oral antiviral medicine that is used for the treatment of chronic hepatitis B virus (HBV) among adults as well as children above 2 years old and weigh at least 22 pounds (10 kilograms) and are suffering from active liver inflammation. This medicine helps in the prevention of certain virus cells from multiplying in the body. In Q1 2021, Bristol-Myers Squibb generated $113.01 million from the Baraclude brand. Baraclude was demanded more in countries like the US, the UK, Japan, China, France, Germany, Italy, and Spain. However, revenue from this brand of medicine has decreased by 7% year-over-year from $122.01 million in Q1 2020.
Eliquis is used to prevent stroke and blood clots in patients with heart rhythm disorder called atrial fibrillation. It is also used to prevent blood clots that can occur in the legs and lungs of people who have just undergone hip or knee replacement surgery. In Q1 2021, Bristol-Myers Squibb generated $2.89 billion from the Eliquis brand of which $1.92 billion was generated from the U.S. Revenue from this brand has increased by 9% year-over-year from $2.64 billion in Q1 2020.
Empliciti is a humanized monoclonal antibody that obstructs a certain protein in the body that can affect tumor cell growth. Monoclonal antibodies target and destroy only certain cells in the body thus protecting healthy cells from damage. This medicine is used to treat multiple myeloma that is bone marrow cancer. In Q1 2021, Bristol-Myers Squibb generated $85.01 million from the Empliciti brand of which $51 million was generated from the U.S. However, revenue from this brand of medicine has decreased by 12% year-over-year from $97.01 million in Q1 2020.
Inrebic production started in August 2019 and is used to treat myelofibrosis in adults. Myelofibrosis is a unique type of bone marrow cancer that affects the body’s ability to produce blood cells. In Q1 2021, Bristol-Myers Squibb generated $16 million from the Inrebic brand of which $15 million was generated from the U.S. Revenue from this brand has increased by 33% year-over-year from $12 million in Q1 2020.
Onureg is a medicine launched in September 2020 and used to treat acute myeloid leukemia (AML) among adults who have received first complete remission with intensive induction chemotherapy with or without recovery of blood cell counts as well as those who are not able to complete intensive curative therapy. In Q1 2021, Bristol-Myers Squibb generated $15 million from the Onureg brand of which $14 million was generated from the U.S.
Opdivo is a cancer medicine that is used alone or in combination with other medicines, given to adults that interfere with the growth and spread of cancer cells in the body. It helps to treat advanced skin cancer, lung cancer, pleural mesothelioma, cancer of the stomach and esophagus, bladder cancer, liver cancer, kidney cancer, and cell cancer of the head and neck. It is also used for the treatment of melanoma, RCC, NSCLC, and CRC. Opdivo is usually given when cancer has spread to other parts of the body and cannot be treated by surgery or when cancer has come back after prior treatment. In Q1 2021, Bristol-Myers Squibb generated $1.72 billion from the Opdivo brand of which $944 million was generated from the U.S. However, revenue from this brand of medicine has decreased by 3% year-over-year from $1.77 billion in Q1 2020.
Orencia is a protein that is used to prevent the immune system to attack healthy tissues such as joints. This medicine is given to patients having autoimmune disorders where the immune system mistakes the body’s cells for invaders and attacks them. Orencia is used to prevent joint damage caused due to rheumatoid arthritis and psoriatic arthritis. In Q1 2021, Bristol-Myers Squibb generated $758.07 million from the Orencia brand of which $536 million was generated from the U.S. Revenue from this brand has increased by 6% year-over-year from $714.07 million in Q1 2020.
Pomalyst/Imnovid helps to increase immune responses to help slow tumor growth. It is used to treat patients having multiple cancer resulting from a progressive blood disease and have already received at least two prior therapies without success. It is used to treat AIDS and HIV patients. In Q1 2021, Bristol-Myers Squibb generated $773.07 million from the Pomalyst/Imnovid brand of which $512 million was generated from the U.S. Revenue from this brand has increased by 8% year-over-year from $713.07 million in Q1 2020.
Reblozyl was launched in April 2020 and used to treat a blood disorder called beta-thalassemia. Beta-thalassemia is a disorder in which the body does not produce enough hemoglobin which carries oxygen from the blood to tissues and organs. Reblozyl is used to treat anemia in adults which causes a deficiency of red blood cells in the body. In Q1 2021, Bristol-Myers Squibb generated $112.01 million from the Reblozyl brand of which $98 million was generated from the U.S. Revenue from this brand has increased by 1300% year-over-year from $8 million in Q1 2020.
Revlimid is an oral immunomodulatory drug that is used to slow tumor growth. Revlimid is given to a patient suffering from bone marrow cancer, after a stem cell transplant. It is also used to treat anemia and mantle cell lymphoma after other medications have failed. In Q1 2021, Bristol-Myers Squibb generated $2.94 billion from the Revlimid brand of which $1.96 billion was generated from the U.S. Revlimid alone accounts for 27% of the revenue earned by Bristol-Myers Squibb Company in Q1 2021. Revenue from this brand has increased by only 1% year-over-year from $2.92 billion in Q1 2020.
Sprycel is an oral inhibitor used to slow down the body’s growth and spread of cancer cells. It is prescribed to adults and children aged one year and above who are suffering from a type of blood cancer called Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). In Q1 2021, Bristol-Myers Squibb generated $470.04 million from the Sprycel brand of which $275 million was generated from the U.S.However, revenue from this brand of medicine has decreased by 10% year-over-year from $521.05 million in Q1 2020.
Vidaza injection is used to restrict the growth and spread of cancer cells and is used to treat myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia (CMMoL). In Q1 2021, Bristol-Myers Squibb generated $54 million from the Vidaza brand of which only $5 million was generated from the U.S. However, revenue from this brand of medicine has decreased by 66% year-over-year from $158.01 million in Q1 2020.
Yervoy is a cancer medicine that is used to treat certain types of cancers related to the skin, lungs, kidneys, and liver. Yervoy is given when cancer has spread to other parts of the body and which cannot be removed by surgery. In Q1 2021, Bristol-Myers Squibb generated 4% revenue amounting to $456.04 million from the Yervoy brand of which $294 million was generated from the U.S. Revenue from this brand has increased by only 15% year-over-year from $396.04 million in Q1 2020.
Zeposia was launched in June 2020 and is an oral drug used to treat relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease among adults. In Q1 2021, Bristol-Myers Squibb generated $18 million from the Zeposia brand of which $13 million was generated from the U.S.
Bristol-Myers Squibb’s revenue from other brands includes all the brands which have lost exclusivity in major markets, OTC brands, and royalty revenue. In Q1 2021, the company generated $339.03 million from other brands. However, revenue from this segment has decreased by 19% year-over-year from $418.04 million in Q1 2020.
Bristol-Myers Squibb Company is an American-based Pharmaceutical company and its origin dates back to 1885 when the Squibb Corporation was established by Dr. Edward Robinson Squibb and in 1887 when William Bristol and John Myers purchased Clinton Pharmaceutical company which was renamed as Bristol-Myers company. The two companies were then officially merged to form Bristol-Myers Squibb Company in 1989. Its headquarter is in New York in the U.S. In 1929 Bristol-Myers Company went public and its common stocks are traded on the New York Stock Exchange under the trading symbol “BMY”
The company manufactures and sells an array of medicines for critical diseases. Particularly it focuses on 4 areas that are immune science, Oncology, Fibrosis, and Cardiovascular. Since 2009 it has acquired Medarex, ZymoGenetics, iPierian, Flexus Biosciences, Padlock Therapeutics, IFM Therapeutics, and Clegen. Some of its major competitors are Daiichi Sankyo, Regeneron Pharmaceuticals, Gilead Sciences, Edwards Lifesciences, Lonza, Catalent, Pfizer, Johnson & Johnson, etc.
Did you like Bristol-Myers Squibb’s Revenue Breakdown statistic?
Access thousands of more such key performance indicator data points, on listed companies, with Business Quant.
You can also get started for free.
Always know what you’ll pay. No hidden costs or surprises.
* Billed annually, local taxes extra.
* Local taxes extra.